Fenofibrate for Patients With COVID-19 Requiring Hospitalization
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Corona Virus Disease (COVID-19)
- Respiratory Distress Syndrome
- SARS CoV-2 Infection
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 85 years
- Gender
- Both males and females
Description
This is an open-label run-in followed by a randomized, double-blind drug treatment study of COVID-19 infected patients requiring inpatient hospital admission. Open-label patients will be matched at least 1:10 with observational retrospective Propensity score-matched (PSM) patients' medical files. Th...
This is an open-label run-in followed by a randomized, double-blind drug treatment study of COVID-19 infected patients requiring inpatient hospital admission. Open-label patients will be matched at least 1:10 with observational retrospective Propensity score-matched (PSM) patients' medical files. The double-blinded step will be randomized 2:1 to daily Fenofibrate or placebo for 10 days or hospital discharge.
Tracking Information
- NCT #
- NCT04661930
- Collaborators
- Barzilai Medical Center
- Investigators
- Principal Investigator: Shlomo Mayaan, MD Barzilai Medical Center Study Director: Mahram Nassar, MD Barzilai Medical Center Principal Investigator: Yaakov Nahmias, PhD Hebrew University of Jerusalem
Get Well Soon